<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011474</url>
  </required_header>
  <id_info>
    <org_study_id>2018-10-013</org_study_id>
    <nct_id>NCT05011474</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration</brief_title>
  <acronym>MANT3_ASC</acronym>
  <official_title>Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inbo Han</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and efficacy of autologous adipose-derived mesenchymal stem cell&#xD;
      spheroids pretreated with matrillin-3 in chronic low back pain patients with lumbar&#xD;
      intervertebral disc degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This clinical trial is a Phase 1/2a, open and researcher-led clinical trial. Subjects will be enrolled in succession, signed informed consent, and administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 to each eligible subject meeting all selection criteria.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection</measure>
    <time_frame>During Clinical Trial Period</time_frame>
    <description>It will be considered safe and tolerated in the absence of the following:&#xD;
Grade 3 (NCI grading system) or higher adverse reactions related to cell products&#xD;
Any evidence that the cells are contaminated with infectious substances&#xD;
Any evidence that cells show tumorigenic potential</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmation of the degree of pain improvement in VAS</measure>
    <time_frame>before and at 1 week, 1, 3, 6 months after stem cell injection</time_frame>
    <description>on a scale of 0 to 10, with 0 meaning no pain and 10 meaning the worst pain you can imagine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmation of the degree of improvement in disability (ODI)</measure>
    <time_frame>before stem cell injection and at 1 week, 1, 3, and 6 months after injection</time_frame>
    <description>on a scale of 0 to 3, with 0 meaning no disability and 10 meaning severe disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmation of increase in water content in the nucleus using MRI</measure>
    <time_frame>before stem cell injection and at 1 and 6 month after injection</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3</intervention_name>
    <description>Adipose-derived mesenchymal stem cells isolated from subject's adipose tissue are pretreated with matrillin 3 and produced in spheroid form.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients aged 19-70 years&#xD;
&#xD;
          -  Among the subjects with low back pain, conventional conservative treatment is&#xD;
             performed, but the back pain or hip pain persists for more than 3 months, and it is&#xD;
             determined that the cause of the back pain is a degenerative disc (MRI checks for a&#xD;
             degenerative disc)&#xD;
&#xD;
          -  Has Oswestry Disability score(ODI) ≥ 30%&#xD;
&#xD;
          -  Has Visual Analogue Scale(VAS) ≥ 4&#xD;
&#xD;
          -  Between lumbar 1-sacral 1, Magnetic Resonance Imaging (MRI) grade according to the&#xD;
             Pfirrmann classification is 3~4.&#xD;
&#xD;
          -  Has one or two degenerative lumbar discs identified by MRI (Confirmation of low back&#xD;
             pain due to disc through various nerve block procedures.)&#xD;
&#xD;
          -  Consent was prepared for stem cell administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient requiring surgery due to severe pain in lower extremities due to severe nerve&#xD;
             compression due to severe lumbar stenosis or prolapse of lumbar nucleus.&#xD;
&#xD;
          -  patient with spinal instability, spondylitis, or vertebral fracture&#xD;
&#xD;
          -  type 3 Modic change is in an endplate&#xD;
&#xD;
          -  Patient whose disc height has decreased by more than 1/2 due to severe disc&#xD;
             degenerative change&#xD;
&#xD;
          -  Patient with severe osteoporosis (The average value of the T score in the lumbar spine&#xD;
             bone density test is -2.5 or less)&#xD;
&#xD;
          -  has undergone surgery, such as disc resection, on the disc to which the cells will be&#xD;
             administered&#xD;
&#xD;
          -  Patient who received lumbar epidural steroid injection 3 weeks before cell&#xD;
             administration&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Among female patients who are likely to become pregnant during the clinical trial, who&#xD;
             do not use medically acceptable methods of contraception&#xD;
&#xD;
               -  medically acceptable methods of contraception: condom, Oral contraception lasting&#xD;
                  for at least 3 months, Has received an infusion pill before 3 months, using an&#xD;
                  injectable or implantable contraceptive, or installed an intrauterine&#xD;
                  contraceptive device&#xD;
&#xD;
          -  has a history of psychiatry or who are currently undergoing treatment, who judged that&#xD;
             it is difficult to proceed with the clinical trial under the judgment of the&#xD;
             researcher&#xD;
&#xD;
          -  Patient with drug or alcohol addiction who cannot understand the purpose and method of&#xD;
             this clinical trial&#xD;
&#xD;
          -  Patient who participated in other clinical trials within 3 months prior to&#xD;
             participation in the trial&#xD;
&#xD;
          -  Patient who may affect this clinical trial due to serious medical conditions&#xD;
             (hypertension not controlled by drugs, diabetes not controlled by drugs, cirrhosis,&#xD;
             kidney failure, tumors)&#xD;
&#xD;
          -  Patient with a history of malignant tumors within the last 5 years&#xD;
&#xD;
          -  has a history of administration of cell therapy products&#xD;
&#xD;
          -  Other persons who have clinically significant findings deemed inappropriate for this&#xD;
             clinical trial due to medical judgment by the person in charge of the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHA University, CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://sites.google.com/view/inbolab/home</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CHA University</investigator_affiliation>
    <investigator_full_name>Inbo Han</investigator_full_name>
    <investigator_title>Professor, Spine Neurosurgeon, Bundang CHA Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

